51本色

Dr. Farahnaz Rayatdoost is a postdoctoral fellow and junior group leader at Ulm University Hospital鈥檚 Institute of Clinical and Experimental Trauma Immunology (ITI), led by Prof. Dr. Markus Huber-Lang. Her research operates at the translational interface of coagulation, haemostasis, platelet biology, and immunohaematology. She specifically investigates the pathophysiological crosstalk driving acute coagulopathy, thrombosis, and systemic inflammatory organ injury during trauma, hemorrhagic shock, and sepsis.

Utilizing a comprehensive methodological framework, ranging from clinical cohort studies and human in vitro and ex vivo platforms to complex translational animal models, she explores the mechanistical interactions between platelet activation, plasma cascade dynamics, and innate immune responses. A central goal of her translational work, including strategies for rapid anticoagulant reversal and novel procoagulant therapies, is to resolve critical clinical dilemmas: restoring effective haemostasis while protecting microvascular integrity, tissue perfusion, and end-organ function.

This paradigm of targeted organ protection extends to her immunohaematological research on post-transfusion immune complications. Her primary focus centers on Transfusion-Related Acute Lung Injury (TRALI), a life-threatening condition driven by donor anti-HLA and anti-HNA antibody-mediated pulmonary vascular injury. By decoding the molecular and cellular cascades through which alloantibody binding triggers endothelial dysfunction and microvascular barrier breach, her work aims to identify actionable therapeutic targets and advance safer transfusion strategies. Broadly, her research group strives to optimize clinical management of complex haemostatic failure while safeguarding multi-organ integrity in critically ill patients.

Her research is supported by Margarete von Wrangell Fellowship and Baustein grant from the Medical Faculty of Ulm University.鈥�